

Lightning Talks Session II

Wednesday, January 21, 2026, from 7:15 to 7:45 p.m.

Spatial heterogeneity atlas of prostate cancer evolution (SHAPE): Spatial and genomic landscapes of advanced prostate cancer with and without Lu-PSMA therapy*

Martin Bakht

Dana-Farber Cancer Institute, Boston, MA

Unveiling the metabolic profiles of prostate cancer to anticipate patient response to treatment*

Andrea Brunello

University of Bern, Bern, Switzerland

Monitoring tumor evolution and phenotypic diversity in metastatic prostate cancer using liquid biopsy profiling*

Irene Casanova-Salas

Vall d'Hebron Institute of Oncology, Barcelona, Spain

Integrating multi-omic datasets investigating stress response biology decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance*

Dimitrios Doultzinos

University of Oxford, United Kingdom

Baseline prostate-specific antigen levels in men aged 65 to 80 and fatal prostate cancer: Implications for risk-stratified screening among older men*

Hannah E. Guard

Harvard TH Chan School of Public Health, Boston, MA

Therapeutic targeting of eIF4E cap-binding domain reveals control of lineage fate in prostate cancer*

Rashmi Mishra

Fred Hutch Cancer Center, Seattle, WA

Cooperativity between DNA methylation and EZH2 activity drives neuroendocrine phenotype in advanced prostate cancer

Richa Singh

Weill Cornell Medicine, New York, NY

The TIP60 acetyltransferase complex is a critical dependency in neuroendocrine prostate cancer through its role as a critical coactivator of MYCL downstream of ASCL1*

Zhen Sun

Memorial Sloan Kettering Cancer Center, New York, NY